Literature DB >> 10757341

Problems in the differential diagnosis of endometrial hyperplasia and carcinoma.

S G Silverberg1.   

Abstract

The differential diagnosis of endometrial hyperplasia and well-differentiated endometrioid adenocarcinoma is complicated not only by the resemblance of these lesions to each other, but also by their tendency to be overdiagnosed (particularly hyperplasia) on the background of polyps, endometritis, artifacts, and even normally cycling endometrium. Atypical hyperplasia may also be overdiagnosed when epithelial metaplastic changes occur in simple or complex hyperplasia without atypia. Low-grade adenocarcinomas are best recognized by architectural evidence of stromal invasion, usually in the form of stromal disappearance, desmoplasia, necrosis, or combinations of these findings between adjacent glands. Endometrioid adenocarcinomas are usually Type 1 cancers associated with manifestations of endogenous or exogenous hyperestrogenic stimulation and a favorable prognosis. Subtypes include adenocarcinomas with squamous differentiation and secretory, ciliated cell and villoglandular variants. Rules and pitfalls in the grading of endometrioid adenocarcinomas and the estimation and reporting of myometrial invasion are presented.

Entities:  

Mesh:

Year:  2000        PMID: 10757341     DOI: 10.1038/modpathol.3880053

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  33 in total

1.  Stromal p16 expression differentiates endometrial polyp from endometrial hyperplasia.

Authors:  Suzuko Moritani; Shu Ichihara; Masaki Hasegawa; Akari Iwakoshi; Sakae Murakami; Tomoko Sato; Tomomitsu Okamoto; Yoshio Mori; Hajime Kuhara; Steven G Silverberg
Journal:  Virchows Arch       Date:  2012-07-07       Impact factor: 4.064

2.  Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.

Authors:  James V Lacey; George L Mutter; Marisa R Nucci; Brigitte M Ronnett; Olga B Ioffe; Brenda B Rush; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz; Mark E Sherman
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

3.  Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.

Authors:  Anthony B Costales; Kathleen M Schmeler; Russell Broaddus; Pamela T Soliman; Shannon N Westin; Pedro T Ramirez; Michael Frumovitz
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

4.  Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus.

Authors:  Mallory E Lindberg; Genna R Stodden; Mandy L King; James A MacLean; Jordan L Mann; Francesco J DeMayo; John P Lydon; Kanako Hayashi
Journal:  Biol Reprod       Date:  2013-07-11       Impact factor: 4.285

5.  Risk factors for developing endometrial cancer after benign endometrial sampling.

Authors:  Michelle L Torres; Amy L Weaver; Sanjeev Kumar; Stefano Uccella; Abimbola O Famuyide; William A Cliby; Sean C Dowdy; Bobbie S Gostout; Andrea Mariani
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

6.  Multilayered, Hyaluronic Acid-Based Hydrogel Formulations Suitable for Automated 3D High Throughput Drug Screening of Cancer-Stromal Cell Cocultures.

Authors:  Brian J Engel; Pamela E Constantinou; Lindsey K Sablatura; Nathaniel J Doty; Daniel D Carson; Mary C Farach-Carson; Daniel A Harrington; Thomas I Zarembinski
Journal:  Adv Healthc Mater       Date:  2015-06-09       Impact factor: 9.933

Review 7.  [Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].

Authors:  F Kommoss; S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

8.  Sox9 overexpression in uterine epithelia induces endometrial gland hyperplasia.

Authors:  Gabriel Gonzalez; Shyamin Mehra; Ying Wang; Haruhiko Akiyama; Richard R Behringer
Journal:  Differentiation       Date:  2016-06-01       Impact factor: 3.880

9.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

10.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.

Authors:  Jessica L Bowser; Michael R Blackburn; Gregory L Shipley; Jose G Molina; Kenneth Dunner; Russell R Broaddus
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.